Novo Nordisk Takes The Plunge Into Alzheimer's With Phase III Semaglutide Trial

GLP-1 Agonist Linked To Inflammation Control

 
• By Andrew McConaghie
  
Novo Nordisk
Novo Nordisk is making a calculated gamble on semaglutide working in Alzheimer's disease.

More from Business

More from Scrip